The biggest checkbook in aging science belongs to a government. That changes the questions.

The second Global Healthspan Summit wraps up today in Riyadh. Its host, the Hevolution Foundation, was created by Saudi royal decree, describes an annual budget of up to $1 billion, and says it has committed $400 million to aging research over the past three years, which makes it the largest philanthropic funder of healthspan science in the world. It put $40 million behind the XPRIZE Healthspan competition and $21 million into the Buck Institute. This year's theme is "Architecting the Future." The sessions are about investment trends, philanthropy and health systems. We would like to know how many are about sleep.

Why the source of money matters. Hevolution's own framing cites a global healthspan gap of about ten years — a life expectancy of 73.4 against 63.7 years in good health. That gap is the right target. The question is what kind of money aims at it. Venture money wants a product in seven years; a sovereign foundation can wait twenty, which is a real advantage for basic biology. But money of every kind funds the questions it finds interesting, and the questions that get asked in Riyadh this week are mostly about molecules.

Ben’s take

I have sat on the receiving end of enough pitches to know that the funder's horizon shapes the science more than the scientist's curiosity does. Sovereign money has the longest horizon in the room and the least accountability to anyone outside it. Watch two things over the next few years: how much of the $400 million goes to work that could not be sold back to anyone, and how much lands in companies that will. The first number is the one that matters for you.

Loree’s take

The ten-year gap Hevolution quotes is mostly made of musculoskeletal disease, mental illness, metabolic disease and the long decline that comes from not moving. The interventions with the strongest evidence against those are not on a drug-discovery agenda, because they are not drugs. A summit can fund the biology of aging and still miss the biology of a walk.

What to watch. The XPRIZE semifinalists are due this spring; the judging criterion is restored function in older adults within a year, which is a better yardstick than most of the industry uses. If the sovereign money holds the field to that standard, it will have done something venture rarely does. If it funds biomarkers, it will have bought a more expensive version of the same trap.